JNJ 63871860

Drug Profile

JNJ 63871860

Alternative Names: E coli bioconjugate vaccine - GSK/Janssen; Expec 4v Conjugate; ExPEC vaccine - GSK/Janssen; ExPEC4V; Extra-intestinal pathogenic Escherichia coli vaccine - GSK/Janssen; JNJ-1860; JNJ-63871860; JNJ-860/EcoXyn-4V

Latest Information Update: 17 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlycoVaxyn
  • Developer GlycoVaxyn; Janssen Pharmaceuticals
  • Class DNA vaccines; Escherichia coli vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Escherichia coli infections; Urinary tract infections

Most Recent Events

  • 01 Nov 2017 Johnson and Johnson announces intention to submit NDA and MAA to US FDA and EMA for Bacterial infection in 2021 (Johnson and Johnson pipeline, October 2017)
  • 01 Aug 2016 Janssen Pharmaceutical completes a phase I trial in Escherichia coli infections (Prevention, In volunteers) in Japan (IM) (NCT02748967)
  • 12 May 2016 Phase-I clinical trials in Escherichia coli infections (Prevention, In volunteers) in Japan (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top